2021 MTF/SAEMF Toxicology Research Grant - $10,000

"Genotypes Associated with Dosing and Relapse in Patients with OUD Receiving Buprenorphine”

The FDA uses guidelines created by the Clinical Pharmacogenomics Implementation Consortium (CPIC) on the drug labels of certain drugs that state that genetic testing is required. Although the FDA states that genetic testing is required or strongly recommended for certain drugs many healthcare institutions and hospitals have not started following these FDA pharmacogenomic recommendations. Our research proposal will test for the specific genotypes for which the FDA recommends testing.


  • Cynthia Santos, MD

    Cynthia Santos, MD

    Rutgers New Jersey Medical School